Skip to main content
. Author manuscript; available in PMC: 2011 Mar 18.
Published in final edited form as: Adv Drug Deliv Rev. 2009 Nov 24;62(4-5):518–531. doi: 10.1016/j.addr.2009.11.021

Table 4.

Summary of surface modifications of dendrimer-based nanocarriers investigated for targeting anti-HIV drugs to different cells/tissues/organs

Anti-HIV drugs Surface modifications Cells/tissues/organs Reference
3TC Mannose conjugated to dendrimer surface HIV-1 infected MT-2 cells [95]
EFV t-Boc-glycine and mannose conjugated separately to dendrimer surface M/M cells [96]